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Adjuvant chemotherapy for solid tumors based on platinum-derived compounds
such as cisplatin is the treatment of choice in most cases. Cisplatin triggers signaling
pathways that lead to cell death, but it also induces changes in tumor cells that mod-
ify the therapeutic response, thereby leading to cisplatin resistance. We have
recently reported that microRNA-7 is silenced by DNA methylation and is involved in
the resistance to platinum in cancer cells through the action of the musculoaponeur-
otic fibrosarcoma oncogene family, protein G (MAFG). In the present study, we first
confirm the miR-7 epigenetic regulation of MAFG in 44 normal- and/or tumor-paired
samples in nonsmall-cell lung cancer (NSCLC). We also provide translational evi-
dence of the role ofMAFG and the clinical outcome in NSCLC by the interrogation of
two extensive in silico databases of 2019 patients. Moreover, we propose thatMAFG-
mediated resistance could be conferred due to lower reactive oxygen species pro-
duction after cisplatin exposure. We developed specifically selected aptamers
against MAFG, with high sensitivity to detect the protein at a nuclear level probed by
aptacytochemistry and histochemistry analyses. The inhibition of MAFG activity
through the action of the specific aptamer apMAFG6F increased the levels of reac-
tive oxygen species production and the sensitivity to cisplatin. We report first the spe-
cific nuclear identification of MAFG as a novel detection method for diagnosis inthis work.
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2 Vera-Puente et al October 2018NSCLC, and then we report that MAFG modulates the redox response and confers
cell protection against free radicals generated after platinum administration, thus
also being a promising therapeutic target. (Translational Research 2018; 200:117)Abbreviations: ATT = adjacent tumor tissues; CDDP = cisplatin; MAFG = musculoaponeurotic
fibrosarcoma oncogene family, protein G; miR-7 = microRNA-7; NSCLC = nonsmall-cell lung
cancer; qMSP = quantitative methylation-specific PCR; qRT-PCR = quantitative real-time PCR;
ROS = reactive oxygen species; TCC = Moffitt’s Total Cancer Care; TCGA = The Cancer
Genome AtlasAT A GLANCE COMMENTARY
Vera-Puente O et al.Background
We have recently reported that microRNA-7 is
silenced by DNA methylation and is involved in
the resistance to platinum in cancer cells through
the action of the musculoaponeurotic fibrosar-
coma oncogene family, protein G (MAFG).
Translational Significance
In the present manuscript, we study the molecular
mechanism underlying cisplatin (CDDP)-resis-
tance mediated by MAFG in human cancer cell
lines by analyzing the reactive oxygen species
production after CDDP treatment. We have also
identified highly-specific aptamers against MAFG
that modulate its activity. The final intention of
our work is to provide new tools for the diagnosis
and therapeutic treatment of CDDP-resistant
tumors by targeting MAFG with aptamers.INTRODUCTION
Cisplatin (CDDP) is the current and most widely
used chemotherapeutic agent in solid malignancies,
including lung and ovarian cancers. CDDP is a plati-
num compound that binds to and crosslinks DNA, thus
inducing apoptosis in cancer cells.1,2 CDDP has also
been reported to generate an increase in oxidative
stress by increasing levels of the superoxide anion,
H2O2, and hydroxyl radicals that can lead to cell death,
enhancing CDDP action.3,4 Despite a reasonable rate
of initial response, however, CDDP treatment fre-
quently results in chemoresistance development, lead-
ing to therapeutic failure in these tumor types. Many
studies and reviews in the last 30 years have centered
on gaining insight into the molecular mechanisms that
account for the CDDP-resistant phenotype of tumor
cells, which could provide crucial information for
treatment resensitizing.4,5 A number of events have
been proposed to underlie this phenomenon. One such
event consists of the ability of cancer cells to overcomethe reactive oxygen species (ROS) generated by
CDDP, thus avoiding apoptosis. The complex cellular
response against ROS is mainly mediated through the
antioxidant response element (ARE), nuclear factor
(erythroid-derived 2)-like 2 (NRF2), and the small
MAF proteins (sMAFs) family of transcription fac-
tors.6 The accumulation of reactive oxygen or nitrogen
species in the cell triggers the translocation of NRF2 to
the nucleus, where it interacts with sMAFs. NRF2-
sMAF heterodimers are the predominant complexes
that bind to the ARE and promote the transcription of
detoxification genes.7-12 An overexpression of these
elements could be responsible for acquired resistance
to CDDP. In fact, we recently reported that miR-7
hypermethylation-derived deficiency mediates CDDP
resistance and identified MAFG as a miR-7-direct tar-
get gene that is upregulated in CDDP-resistant tumor
cells. Furthermore, miR-7 overexpression resulted in a
repression of MAFG expression in lung and ovarian
human cancer cells.13 Our previous results suggest a
relevant role for MAFG conferring resistance to ROS-
inducing compounds such as CDDP via the increased
detoxification of free radicals. In addition, despite its
important role in ROS detoxification, little is known
about the involvement ofMAFG in human diseases.
In the present study, we have studied in depth the
role of the miR-7 and/or MAFG axis in acquired resis-
tance to CDDP in lung cancer and explored MAFG as
a possible diagnostic and therapeutic target by develop-
ing aptamers that show high affinity for the protein as a
novel approach for chemotherapy resensitization.
Aptamers are a recently developed alternative to spe-
cific biomolecule recognition; they are single-stranded
nucleic acid molecules with high affinity for a particu-
lar target due to their ability to fold into tertiary shapes.
These oligonucleotides are generated from an in vitro
selection process and can be considered a novel alter-
native in therapy, diagnosis, and in the development of
new biotechnological tools.14-16MATERIALS AND METHODS
Cell cultures and treatments. The human cancer cells
H23 and A2780, and the HEK-293T epithelial cells
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ECACC (Sigma, Spain) and cultured as recommended.
The CDDP-resistant variants H23R and A2780R were
established in our laboratory as previously
described,13,17 using CDDP (Farma Ferrer, Spain) for
cell viability assays. To validate the results obtained
from the resistant cell lines established in our labora-
tory, we also used the CDDP-resistant lung cancer cell
line H1299, with IC50 over 7, purchased from ATCC
and maintained as recommended. Cell authentication
is shown in Supplementary Table 3.
Clinical sample and data collection. Fresh-frozen
tumors (T) and adjacent-tumor tissue (ATT)-paired
samples were obtained from 22 patients with non-
small-cell lung cancer (NSCLC) from La Paz Uni-
versity Hospital. All patients had both a perioperative
positron emission tomography-computed tomography
scan showing localized disease and a pathological con-
firmation of stages after having undergone a complete
resection for a histologically confirmed early NSCLC.
Follow-up was conducted according to the criteria of
the medical oncology division from the institution. In
addition, five saliva samples from healthy donors were
used as controls. All samples were collected after the
approval of the appropriate Human Research Ethics
Committee at the contributing center, including an
informed consent within the context of research. Clini-
cal, pathological, and therapeutic data were recorded
by an independent observer, and a blind statistical anal-
ysis was performed on the data.
RNA isolation, RT-PCR, and quantitative RT-PCR. Total
RNA from surgical samples was isolated, reverse tran-
scribed and quantitative real-time polymerase chain
reaction (qRT-PCR) analysis was performed as previ-
ously described.17,18 Samples were analyzed in tripli-
cate using the HT7900Real-Time PCR system
(Applied Biosystems, USA). Relative expression levels
were calculated according to the comparative threshold
cycle method (2¡DDCt) using GAPDH as an endoge-
nous control gene and RNU48 as endogenous control
miRNA. Primers and probes for expression analysis
were purchased from Applied Biosystems (MAFG: Hs
01034678_g1; GAPDH: Hs03929097_g1; miRNA-7:
000268; and RNU48: 001006).
For semiquantitative RT-PCR, 500 ng of total RNA iso-
lated from cell lines was used for RT reaction using Prime-
Script RTMaster (Clontech-Takara, USA) and subsequent
semiquantitative PCR using Promega PCRMix (Promega,
USA) as previously described.19 Relative quantification
was performed by measuring the intensity of band ampli-
fied using ImageJ software. Primers for HMOX1 (F: 50-
TGAGTTTCAAGTATCCTTGTTGACAC-30; R: 50-CTT
GGTCTAACTTTTGTGTGAAATAA-30), MAFG (F: 50-
TCAGATTTCAGAGGAATACCCAGCAG-30; R: 50-TGATCACCAGTCAGAAGTGTACACAC-30), and GAP
DH (F: 50-GAGAGACCCTCACTGCTG-30; R: 50-
GATGGTACATGACAAGGTGC-30) were designed to
include the probe from the array in order to assure the cor-
rect transcript identification.
DNA extraction, bisulfite modification, and quantitative
methylation-specific PCR.DNA from a total of 44 surgi-
cal samples from patients with NSCLC was isolated
and bisulfite modified as previously described18 and
was used to analyze miRNA-7 methylation status. For
quantitative methylation-specific PCR, we used the
primer and/or probe set to detect levels of either meth-
ylation (F: 50-GGGTGGGGTTTTTTAAGAATC-30;
R: 50-ACATTCTCCTCCTTCGATCG-30; Probe: 50-
FAM-ACCCCTCTTCGTTCTCGAT-30) or unmethy-
lation (F: 50-GGGGTGGGGTTTTTTAAGAATT-30;
R: 50-ATAACATTCTCCTCCTTCAATCA-30; Probe:
50-VIC-ACCCCTCTTCATTCTCAAT-30). All assays
were performed in duplicate using the QuantiTect Mul-
tiplex PCR Kit (Qiagen, USA) and the HT7900
Applied Biosystems. The percentage of methylation of
each sample was calculated according to previously
published reports.20
Western blot analysis. Proteins (30 mg) from cell
lysates were resolved by sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and transferred
to Immobilon-P membranes (Millipore Iberica SA,
Madrid, Spain). Membranes were incubated with
anti-Nrf2 at 1:10,000, anti-HO-1 at 1:10,000
(Abcam), and anti-b -actin at 1:100,000 (Sigma,
Madrid, Spain). Peroxidase-conjugated secondary
antibodies (1:10,000) were used to detect proteins by
enhanced chemiluminescence detected by Advance
Western-blotting Detection Kit (GE Healthcare, Bar-
celona, Spain).
In silico databases: The Cancer Genome Atlas and
Total Cancer Care. The Cancer Genome Atlas (TCGA)
data: We obtained RNA sequencing data for the
MAFG of 984 NSCLC tumors from the TCGA. The
raw reads were quantified by RSEM21 in order to deter-
mine the read counts for each gene and miRNA (calcu-
lated separately). Then, we filtered out genes and
miRNAs having less than one count-per-million reads
in all samples. The normalization process was per-
formed with trimmed mean of M values22 to obtain the
MAFG sequence count data in all patients.
Total Cancer Care (TCC): We obtained MAFG gene
expression data for 1035 lung cancer samples from the
Moffitt Cancer Center Total Cancer Care Bioreposi-
tory23 that were assayed on a custom Affymetrix 2.0
microarray. Normalized intensity values for MAFG
probe sets were obtained and the probe with highest
average intensity was retained for gene expression
analysis.
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tured in 96-well black plates at density of 10,000 cells/-
well. Cells were treated with 6 different doses of CDDP
for 24, 48, and 72 hours. Then treatments were removed
and cells were incubated with the fluorescent probe
20,70-dichlorodihydrofluorescein diacetate (H2DCFDA)
(10 mM) for 45 minutes in Roswell Park Memorial Insti-
tute medium (FBS-free). Cells were washed twice with
Roswell Park Memorial Institute (10% FBS), and fluo-
rescence was recorded in a Fluostar Optima at 520 nm
after excitation at 485 nm. At the end of the experiment,
solutions were replaced for fresh media containing MTT
(0.5 mg/mL concentration) in order to determinate via-
bility. ROS production was calculated dividing the mean
H2DCFDA fluorescence by the mean viability. Data
were normalized with respect to basal conditions that
were considered as 100%.
Aptamer selection for MAFG. Selection of DNA
aptamers for MAFG was performed using the systematic
evolution of ligands by exponential enrichment
(SELEX) method with several modifications. First,
MAFG-Myc overexpressed in HEK293T cells were
bound to Myc-agarose beads (Thermo Scientific 20168),
following the supplier’s instructions. The same amount
of lysates from HEK293T cells transfected with empty
vector was immunoprecipitated in parallel and used for
the contraselection step. Synthetic random ssDNA (IBA
Life Sciences, Germany), containing a central random-
ized region of 40 nucleotides flanked by two conserved
18-nucleotide regions in each end (RND40, 50-
GCGGATGAAGACTGGTGT-40N-GCCCTAAATAC-
GAGCAAC-30) was denatured at 95˚C for 10 minutes
and then cooled on ice for 10 minutes. Further steps of
the selection were followed as previously described with
minor modifications.16 Finally, contraselection prepared
as above was performed after round 2 and 5.
 Analysis of aptamer-MAFG complexes by RT-PCR:
The aptamer populations obtained after 3 and 6 rounds
of selection (SEL3MAFG and SEL6MAFG) or
RND40 were incubated at 0.4 nM with 20 pmoles of
MAFG bound to Myc-agarose for 1 hour at 37˚C. In
parallel, the same amount of each aptamer was incu-
bated with the same volume of Myc-agarose resin with-
out MAFG. After centrifugation at 12,000 g for 10
minutes, complexes were washed four times with 250
mL of selection buffer and confirmation the aptamers
presence was performed as described.16
 Enzyme-linked oligonucleotide assay (ELONA):
Aptamers were labeled by PCR using 50 digoxigenin-
labeled F3/50 digoxigenin-labeled R3 primers (IBA
Life Sciences). To assess the enrichment of the
selected population and the affinity of the individual
aptamers for the target, MAFG-Myc (50 ng) was
incubated with the rounds 3, 6 of aptamers or theRND40 library, as previously described with minor
modifications.16 OD405nm values were determined
using a SpectraFluor microplate reader (TECAN,
Barcelona, Spain).
 Aptacytochemistry: HEK293T cells were seeded on
glass coverslips pretreated with poly-L-lysine
(Sigma-Aldrich). After 1624 hours, the cells were
transfected with 0.4 mg of MAFG-Myc plasmid
using Lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions. Twenty-four hours post-
transfection, the cells were fixed with cold methanol
for 20 minutes at ¡20˚C and followed incubation
with aptamer populations SEL3MAFG and SEL6-
MAFG, as described previously.16 Colocalization
was assessed by confocal microscopy using a Nikon
ECLIPSE Ti-e inverted fluorescence microscope
equipped with a Nikon C1 laser scanning confocal
microscope system (Nikon, Tokyo, Japan) and a 60£
oil immersion objective.
 Aptamer cloning, sequencing, and secondary struc-
ture prediction: The dsDNA products with “A”-over-
hangs from SEL6MAFG were cloned onto pGEM-T
Easy-cloning vector (Promega), following the manu-
facturer’s instructions. Individual clones were
sequenced using T7 (50-TAATACGACTCACTA-
TAGGG-30) and Sp6 primers (50-ATTTAGGTGA-
CACTATAGAA-30) provided by the Sequencing
core. Selected ssDNA molecules were subjected to
secondary structure prediction using mFold software
(http://mfold.rna.albany.edu/?q=mfold/DNA-Fold
ing-Form) 41 at 37˚C in 150 mmol/L [Na+] and 1
mmol/L [Mg+2].
Aptacytochemistry and aptahistochemistry with
selected dig-labeled aptamers. Following the method-
ology described above, H23R cells were incubated
with 6 pmol of digoxigenin-labeled aptamers (IBA
Life Sciences) in selection buffer for 1 hour at room
temperature. Subsequently, cells were washed three
times with PBS and incubated with anti-digoxigenin
conjugated with 50 AlexaFluor 488 (R&D systems,
USA) at 1/500 dilution in blocking buffer for 1 hour at
room temperature, as secondary antibody. Finally, the
cells were mounted on glass slides using glycerol-
buffer containing p-phenylenediamine and 1/750 dilu-
tion of Dapi for nuclear staining. Controls were made
by omitting the aptamer. Colocalization was assessed
by confocal microcopy as described in (iii).
The formalin-fixed and paraffin-embedded tissue
sections of patients with lung cancer were baked 15
minutes at 60˚C. Deparaffinization was performed by
two washes of xylene for 10 minutes each. Tissue sec-
tions were rehydrated by a sequential wash in 100%,
90%, 80%, and 70% ethanol and distilled water for 5
minutes each. Antigen retrieval was achieved by heat
Translational Research
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citrate buffer (pH 6.5). Endogenous peroxidase activity
of tissues was blocked with 0.3% H2O2. The primary
binding reaction was performed with 10 pmol/mL of
digoxigenin-conjugated aptamers overnight at room
temperature. The secondary binding reaction was per-
formed with anti-digoxigenin conjugated with POD
(Roche; 1/200 dilution in TBS) for 45 minutes. Stain-
ing was done using the Immunoperoxidase DAB kit
(Master Diagnostica), according to the manufacturer’s
instructions. The sections were counterstained with
hematoxylin.
Cell transfection and viability assays. HEK293 and
H23S/R cells were seeded into 96-well plates then
transfected with 5, 12.5, 25, 75, and 100 nM of MAFG
aptamers or treated with PBS-Mg using Jet Pei Poly-
Plus transfection reagent (PolyPlus Transfection,
USA). The dose of 25 nM aptamer was afterward used
in combination with increased doses of CDDP to assay
viability and ROS production as described above. Via-
bility to aptamers was assayed as previously
described.24 To confirm the aptamer-transfection effi-
ciency, cells were seeded in 24-well plates for aptamer
isolation and confirmation of aptamer transfection by
quantitative analysis as previously described.16 A
Myc-DDK-tagged ORF clone of MAFG the negative
control pCMV6 were used for in transient transfection
(OriGene, USA) in combination with MAFG-aptamers
following the same procedure.
Statistical analysis. The data were compared using the
Chi-squared test or Fisher’s exact test for qualitative
variables, and Student’s t test or the Wilcoxon-Mann-
Whitney test (non-normal distribution) for quantitative
variables. Correlation of quantitative variables was
analyzed by Pearson’s test. For the in silico databases,
the data were stratified for patients with high or low
expression of MAFG according to the median of the
gene expression (TCGA cutoff: 2018 counts per mil-
lion; TCC cutoff: 8.70 of intensity probe). Overall sur-
vival was estimated according to the Kaplan-Meier
method and compared between groups by means of the
Log Rank test. All the P values were two sided, and
the type I error was set at 5%. Statistical analyses were
performed using SPSS 20 software.RESULTS
MAFG overexpression is associated with a poor
prognosis in patients with nonsmall-cell lung cancer.
Previously published studies from our group showed
that the epigenetic regulation of miR-7 through DNA
methylation is a mechanism involved in platinum resis-
tance in cancer cell lines directly regulating the actionof MAFG, which is overexpressed in resistant pheno-
types.13 In the present study, we explored the involve-
ment of the miR-7 and/or MAFG axis in NSCLC
primary tumors. We first analyzed the quantitative
DNA methylation levels of miR-7 and RNA expression
levels of miR-7 and MAFG in a cohort of 22 paired
samples from fresh-frozen T and ATT from patients
with NSCLC (Table I) and controls.
We observed an increase in the data dispersion in the
NSCLC T samples versus the ATTs in miR-7 methyla-
tion and expression levels (Supplementary Table 1).
The higher dispersion was statistically significant in
both groups only when compared with saliva samples
from healthy donors (P = 0.0002; Fig 1A and Supple-
mentary Table 1). A negative tendency in the correla-
tion between the percentage of methylation and
expression levels of miR-7 was found only in the T
samples (Fig 1B). The opposite tendency was found,
toward more expression of MAFG in T samples, when
the percentage of miR-7 methylation increased (Supple-
mentary Figure 1). Neither tendency was statistically
significant, probably due to the limited sample numbers;
however, it is interesting to note that the two samples
that showed the highest dispersion for MAFG expres-
sion presented a miR-7 methylation level over 20%.
To determine whether MAFG expression correlated
with clinical outcome in patients with NSCLC, we
investigated the gene expression levels in 984 patients
with NSCLC from the TCGA database and 1035
patients with NSCLC from the Total Cancer Care Bio-
repository at the Moffitt Cancer Center. When compar-
ing data from both data sets, we observed statistical
significance according to the median level of MAFG
expression; patients with low expression levels had a
clearly increased overall survival compared with the
group of patients with high MAFG expression levels,
with P values of 0.020 and 0.011 for both cohorts,
respectively (Fig 1C).
MAFG overexpression might induce CDDP resistance,
targeting ROS. MAFG is a transcription factor involved
in the detoxification of ROS, whose expression is
increased in the resistant cell phenotypes H23R and
A2780R, which mediates their resistance to CDDP.13
Thus, we explored whether MAFG influenced oxida-
tive stress in our experimental model of paired sensi-
tive and/or resistant cells by analyzing ROS production
in cells after CDDP exposure.
First, we confirmed the response to CDDP at 24,
48, and 72 hours after exposure to the drug for both
cell lines H23S and H23R. H23R cells present a resis-
tance index >3, in accordance with our previous
results25 (Fig 2A). ROS levels were increased in sen-
sitive cells after CDDP treatment compared with
resistant cells, reaching 300% and 159% ROS
Table I. Clinicopathological and experimental data obtained from patients with NSCLC from La Paz University Hospital
miR-7
methylation
miR-7 expression MAFG expression
Patient Histology Sex Stage Chemotherapy ATT (%) T (%) ATT
(2¡DCt)
T
(2¡DCt)
ATT
(2¡DCt)
T
(2¡DCt)
apMAFG3F
(% of PC)
apMAFG6F
(% of PC)
apMAFG11F
(% of PC)
Status OS,
days
1 Adenocarcinoma Female IA No 58.49 NA 0.50 0.19 0.62 0.43 70.81 NA 79.26 Alive 2220
2 Epidermoid Male IB No 5.63 5.35 1.71 2.61 0.65 0.53 84.14 90.93 27.83 Exitus 1022
3 Adenocarcinoma Male IB No 14.98 13.12 1.16 0.31 0.59 0.28 NA 77.11 NA Exitus 3
4 Adenocarcinoma Male NA No 12.47 26.06 1.11 0.51 0.43 4.37 90.61 91.08 87.18 Exitus 626
5 Large Cell Male IIB No 9.20 12.69 0.80 0.34 0.28 0.29 44.69 25.55 21.72 Exitus 62
6 Adenocarcinoma Male IIIA Other 7.28 3.74 2.33 0.38 0.31 2.12 84.77 79.60 40.41 Exitus 228
7 Epidermoid Female IIIB CDDP +Other 8.47 5.69 1.65 1.77 0.58 0.05 67.48 87.21 22.58 Exitus 109
8 Adenocarcinoma Female IIA CDDP +Other 8.37 28.94 0.70 2.42 0.91 0.13 77.15 79.55 59.50 Alive 2260
9 Epidermoid Male IB No 9.41 8.09 1.07 1.17 5.59 0.29 74.31 73.12 NA Alive 1853
10 Adenocarcinoma Male IA No 8.19 38.79 1.00 0.09 1.00 0.04 75.39 69.14 74.06 Exitus 216
11 Adenocarcinoma Female IIIA CBDCA+Other 6.51 6.08 0.99 5.83 1.91 0.20 53.02 35.66 68.15 Alive 2192
12 Epidermoid Male IB CDDP +Other 7.59 30.28 0.92 0.75 2.24 0.81 77.27 92.45 NA Alive 2341
13 Epidermoid Male IIA No 12.44 NA 0.77 1.51 0.70 0.09 88.89 84.07 75.52 Exitus 289
14 Epidermoid Male IIA No 12.66 10.98 2.21 2.07 0.73 0.84 90.76 96.88 NA NA 109
15 Adenocarcinoma Female IIIA CDDP +Other 4.72 3.57 0.73 0.32 0.76 0.49 NA NA NA Alive 2228
16 Adenocarcinoma Male IIB Other 35.35 10.00 0.80 0.31 1.03 0.78 75.77 95.65 94.51 Exitus 888
17 Epidermoid Male IIB CBDCA+Other 8.24 53.19 1.35 1.05 0.57 0.03 74.61 28.90 44.30 Exitus 259
18 Adenocarcinoma Female IB CDDP +Other 10.29 9.42 1.19 2.86 0.38 1.52 95.72 93.75 87.23 Exitus 936
19 Epidermoid Male IIB CDDP +Other 13.67 9.52 1.50 2.87 0.99 0.50 NA NA NA Exitus 1224
20 Epidermoid Male IIIB CBDCA+Other 4.06 13.45 0.80 1.33 0.22 0.43 85.99 NA 2.24 Exitus 603
21 Adenocarcinoma Male IIIA CDDP +Other 9.55 63.07 1.14 0.65 1.11 2.57 NA 67.21 71.08 NA 421
22 Adenocarcinoma Female IIB CDDP +Other 4.43 6.84 0.50 2.07 0.26 2.35 80.30 92.55 78.10 NA 184
Abbreviations: ATT: adjacent tumor tissue; CBDCA: carboplatin; CDDP: cisplatin; NA: not available; NSCLC: non-small cell lung cancer; OS, Overall Survival; % of PC: % of Positive Cells; T: tumor.
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Fig 1. Involvement of miR-7 and MAFG in patients with NSCLC. (A-B) Assessment of miR-7 methylation lev-
els measured by qMSP and expression levels of miR-7 measured by qRT-PCR in fresh samples from a cohort of
22 patients with NSCLC; (A) Left, quantitative methylation percentage of miR-7; right, miR-7 expression levels
in 44 paired samples (ATT and T); (B) Correlation between the methylation percentage of miR-7 and expression
levels of miR-7. For all the analyses, data represent the percentage of methylation according to a previous
report20 and expression levels in 2¡DCt; (C) Analysis of mRNA expression of MAFG in two in silico cohorts of
patients with NSCLC. Survival analysis in 984 (left panel) and 1035 (right panel) NSCLC samples from the
TCGA and TCC, respectively. LogRank test was used for comparisons and P < 0.05 was considered as a signifi-
cant change in OS. NSCLC, non-small cell lung cancer; ATT, adjacent tumor tissue; T, tumor; CPM, counts per
million; TCGA, The Cancer Genome Atlas; TCC, Total Cancer Care. *** P < 0.001
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basal untreated cells, P < 0.001 (Fig 2B). The
response to CDDP and the differences in ROS produc-
tion between sensitive and resistant cells were also
confirmed in A2780S/R ovarian cancer cell lines
(Supplementary Figure 2A), in which we observed an
effect of CDDP treatment after 48 hour of exposure,
consistent with previous reports.13 Moreover, we
found that the expression of ROS-detoxifying genes,
such as HMOX1, NQO1, GSTO2, or GPX7 (Supple-
mentary Table 2), was upregulated in these resistant
cell lines (P < 0.05), according to our reported arrays
under the same previously defined bioinformatics and
statistical criteria13 (GEO GSE84201). We selected
HMOX1 and NRF2 for semiquantitative RT-PCRexpression pattern validation, because of their close
relationship with MAFG action in the detoxification
process. NRF2 expression did not changed after
CDDP treatment; however, the resistant cells showed
higher protein levels of NRF2, and it was also
observed a slight increase in HMOX1 levels (Fig 2C,
D and Supplementary Figure 2B). In addition, we
observed a direct relationship between the expression
of MAFG and the Resistance Index in all our lung
cancer cell lines (Supplementary Figure 2C).
Identification of aptamers binding MAFG. Aptamers
were selected from libraries of oligonucleotides by iter-
ative cycles of selection (SELEX methodology). We
performed 6 rounds of selection and 2 contraselection
rounds (after rounds 2 and 5), using a Myc agarose
Fig 2. Viability assays and reactive oxygen species detection after CDDP treatment in H23 cell lines. (A) Viability to
CDDP in H23S (left) and H23R (right) at 24, 48, and 72 hours and 6 concentrations of CDDP measured by MTT assay;
(B) Increment of ROS production in H23S (left) and H23R (right) after 24, 48, and 72 hours of CDDP treatment; For
(A) and (B), bars represent the mean of at least two independent experiments measured by duplicate§ SD. $: P  0.05
versus basal; $$: P  0.01 versus basal; $$$: P  0.001 were considered as significant change in CDDP resistance and
ROS production; (C) Semiquantitative mRNA expression analysis of downstream genes involved in ROS detoxification
regulated byMAFG, which showed expression changes for H23 in the microarray data (GSE84201,13) (left panel). Rep-
resentative images of MAFG and HMOX1 RT-PCR comparing sensitive and resistant subtypes. Each assay was per-
formed at least three times to confirm the results. (Right panel) Relative intensity quantification of the amplified band
for each gene measured by ImageJ Software. Bars represent the mean of the three independent experiments using the
intensity ofGAPDH as endogenous control and the sensitive subtype of each cell line as calibrator. (D) Immunoblots of
HMOX1, NRF2, and -actin. Images correspond to a representative experiment that was repeated four times with similar
results. Scion Image program was used to quantify band intensities corresponding to immunoblot detection of protein
samples. CDDP, cisplatin; MAFG, musculoaponeurotic fibrosarcoma oncogene family, protein G.
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Volume 200 Vera-Puente et al 9resin that binds the MAFG-Myc protein overexpressed
in HEK293T cells. To assess the enrichment and the
affinity of the population obtained after successive
rounds of selection, we performed three types of
assays: (i) analysis of aptamer-MAFG complexes by
RT-PCR, (ii) ELONA assays, and (iii) aptacytochemis-
try. Quantitative PCR assays were performed using
aptamers that bind to MAFG-resin complexes as a tem-
plate. These assays allowed us to confirm that the
selected aptamers were specific against the target and
not the Myc-agarose resin. The amount of aptamers
recovered in the presence of MAFG was 3 Cts lower
than in that of the RND40 and SEL3MAFG population,
whereas SEL6MAFG was 4.5 Cts lower in the pres-
ence of MAFG (Fig 3A), indicating a higher amount of
aptamers bound in this round. In addition, ELONA
assays showed a statistically significant increase in the
signal of the population obtained after round 6 relative
to round 3 or to the initial RND40 population (Fig 3B).
Finally, we studied the capacity of the aptamer popula-
tion of each round to recognize overexpressed MAFG
in the cells by aptacytochemistry. For this purpose,
HEK293T cells transiently transfected with MAFG-
Myc were incubated with the initial RND40 population
or with that of round 3 or round 6, labeled with Alexa-
488. The results obtained by fluorescence microscopy
indicated that RND40 showed a very low signal with a
diffuse cytoplasmic pattern, whereas SEL3MAFG and
most prominently SEL6MAFG aptamers showed a
high nuclear signal in several cells. This pattern was
very similar to that obtained by incubation with the
Myc antibody (Fig 3C). In view of these results, we
cloned and sequenced the SEL6MAFG population and
identified three sequences (apMAFG3F, apMAFG6F,
and apMAFG11F) with high binding capacity to the
target in the nanomolar range, reaching values of four
times that of the BSA protein (Fig 3D and Supplemen-
tary Table 4). To predict the most stable secondary
structures of the MAFG aptamers, we performed a bio-
informatic analysis of their sequences using mFold
software. Fig 3E illustrates the most probable second-
ary structures of these aptamers, taking into account
the lower free energy (DG).
MAFG aptamers can be used to detect MAFG levels in
NSCLC samples. We next performed aptacytochemistry
on H23S and H23R cells with the individual digoxige-
nin-labeled aptamers apMAFG3F, apMAFG6F, and
apMAFG11F. We observed that individual aptamers
were more present in H23R cells than in H23S, mostly
in the nuclei of the cells and specifically accumulated in
quantifiable dots (Fig 4), according to the cellular locali-
zation of MAFG. Quantification of the number of dots
per nucleus showed remarkable differences betweenH23R and H23S for apMAFG3F and apMAFG6F,
whereas no differences were observed for apMAFG11F
(Supplementary Figure 3). Interestingly, apMAFG3F
was also present in the cytoplasm, whereas apMAFG6F
was preferentially located at the nuclei.
We then took advantage of the aptacytochemistry to
perform an aptamer-based histochemistry in 20 tumor
samples from our cohort of patients with known
mRNA levels of MAFG. We found that aptamers were
able to identify MAFG in the nucleus of various cell
types with differential staining intensity between the
tumors (Fig 5A). To determine the correlation between
the aptahistochemistry and the mRNA levels of
MAFG, we calculated the percentage of cells with pos-
itive staining from the total number of cells computed
at four different areas randomly selected for each sam-
ple. We observed that classifying the patients accord-
ing to their MAFG expression levels, those samples
with higher MAFG levels presented a significant incre-
ment in the percentage of positive cells after aptahisto-
chemistry staining with both apMAFG3F and
apMAFG6F (P < 0.05 and P < 0.01, T test, respec-
tively; Fig 5B).
apMAFG6F increases ROS production and restores cell
sensitivity to CDDP. To gain insight into the biological
effect of the identified aptamers and to optimize the
dose for a functional analysis, we worked with the nor-
mal cell line HEK293T and the sensitive and resistant
phenotypes of the lung cancer cell lines H23S/R.
MAFG aptamer transfection induced similar mortality
curves in the cancer cell lines, while it appeared to
induce less toxicity in HEK293T, which showed better
viability curves for the three aptamers tested (Supple-
mentary Figure 4A). Concentrations higher than 25 nM
induced a high mortality rate in all the cells tested, and
the same effect was also observed when two intermedi-
ate doses selected between the 25 nM and 75 nM con-
centrations were tested in H23R (Supplementary
Figure 4B). The 25 nM concentration was chosen for
functional analysis because it is the minimal dose that
exerts an effect on viability of tumor cells but not nor-
mal cells. The efficiency of aptamer transfection at this
dose was confirmed by quantitative PCR (Supplemen-
tary Figure 4C). We next tested the specificity of the
aptamers for rescuing the sensitivity to CDDP.
Aptamer apMAFG6F decreased the CDDP resistance
at 25 nM (resistance index 2.63 vs 2.0), whereas no
changes were observed for aptamers apMAFG3F or
apMAFG11F (Fig 6A). We confirmed these results in
H1299, an additional lung cancer tumor cell line highly
resistant to CDDP with an IC50 of 10 mg/mL (Fig 6B).
In fact, we verified the ability of apMAFG6F to
increase CDDP sensitivity in H1299, as we observed a
Translational Research
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Fig 4. MAFG localization pattern in H23S and H23R cells measured by aptacytochemistry. Cells were incu-
bated using digoxigenin-labeled aptamers apMAFG3F, apMAFG6F, and apMAFG11F as primary recognition
molecule and Alexafluor 488-conjugated anti-digoxigenin as secondary antibody. Confocal microscopy images
corresponding to the staining of nuclei with Dapi (blue), aptamers (green) and merge are shown. Bar = 25 mm.
MAFG, musculoaponeurotic fibrosarcoma oncogene family, protein G.
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ison with the untransfected cell line. This increase in
sensitivity to the drug was accompanied by a decrease
in MAFG and HMOX1 expression in the cells carrying
apMAFG6F (Supplementary Figure 4D). In addition,
we overexpressed MAFG in H23S cells as we have
done previously13 and combine the overexpression
with apMAFG6F, which rescued the phenotype and
resensitized the cells (Fig 6C). We also confirmed the
success of the overexpression and aptamer transfection
by qRT-PCR (Fig 6D).Fig 3. Analysis of the affinity of the aptamers against MAF
by qPCR comparing absence (dot pattern) or presence (filled
ences in Threshold Cycle (Ct) between the library RND4
(SEL6MAFG). Bars represent the mean § SEM of 23 exp
to MAFG performed by ELONA. MAFG-Myc was plated at
with 50 digoxigenin-labeled aptamers from RND40, SEL3M
mean § SEM of three independent experiments. $$: P < 0.
siently transfected with MAFG-Myc. Cells overexpressing M
gated aptamers from RND40, SEL3MAFG, or SEL6MAF
Fluorescence microscopy images corresponding to the stain
and aptamers (green) are shown. Arrowhead indicates po
aptamer affinity performed by ELONA. Recombinant MAFG
by incubation with 50 digoxigenin-labeled individual aptame
figure represents the mean § SEM of two independent e
apMAGF3F, apMAFG6F, and apMAFG11F obtained by bio
ware taking into account the lower free energy (DG). MAFG
ily, protein G; ELONA, enzyme-linked oligonucleotide assaTo ultimately confirm that apMAFG6F was restor-
ing CDDP sensitivity in H23R cells by acting on the
ROS, we measured ROS production after combining
aptamer transfection and CDDP treatment. We
observed a linear dose-response relationship between
increasing amounts of CDDP and the production of
ROS at 4 mg/mL of CDDP (P < 0.005) in the resistant
cells carrying the apMAFG6F compared with the
untransfected cells. This result was also consistent with
the decrease in cell viability that we also measured in
parallel in this experiment (Fig 7A). SemiquantitativeG. (A) Quantification of aptamer-MAFG complexes
pattern) of MAFG protein. Figure shows the differ-
0 and the selection rounds 3 (SEL3MAFG) and 6
eriments; (B) Specificity binding assay of aptamers
50 ng/well in 96-well plates followed by incubation
AFG, and SEL6MAFG. The figure represents the
01; (C) Aptacytochemistry in HEK-293T cells tran-
AFG were incubated with 50 Alexafluor 488-conju-
G (upper panel) or Myc antibody (lower panel).
ing of nuclei with Hoechst (blue), antibodies (red),
sitive cells. Bar = 13 mm; (D) Study of individual
was plated at 50 ng/well in 96-well plates followed
rs apMAGF3F, apMAFG6F, and apMAFG11F. The
xperiments; (E) Secondary structures of aptamers
informatics sequence analysis using the mFold soft-
, musculoaponeurotic fibrosarcoma oncogene fam-
y.
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their expression in aptamer-transfected H23R cells
after platinum treatment compared with H23R
(Fig 7B).DISCUSSION
The study of epigenetic, transcriptional, and post-
transcriptional regulatory mechanisms of genes and
miRNAs will help to elucidate key players involved in
resistance to chemotherapy drugs. Current treatments
may be improved and new ones developed based on
the genetic and epigenetic profiles of various cancer
patients, thus leading to personalized therapies. The
search for new biomarkers for survival, prognosis, and
drug-resistance in cancer is a wide-open field for
exploration and investigation. In fact, despite signifi-
cant scientific effort in recent decades, we have not yet
overcome the strategic challenge of restoring sensitiv-
ity to platinum-derived drugs that are still the paradigm
treatment for many malignancies, including lung
cancer.
For NSCLC, differential expressions have been
reported for several miRNAs, such as miR-200c in
NSCLC cell lines,26 or miR-138 in the A549 CDDP-
resistant subtype cell line, in comparison with the
parental A549 and how their enhanced expression
increased the response to CDDP.27 However, there are
very few studies linking the role of miRNA methyla-
tion with tumor development or clinical outcomes such
as miR-34a.28,29 We have previously reported that
hypermethylation of regulatory regions of miR-7s may
predict relapse in platinum-treated patients with ovar-
ian cancer. We intended first to deepen our understand-
ing of this aspect in a cohort of 22 paired samples from
patients with NSCLC. We found similar methylation
levels of miR-7 in tumor samples and in normal adja-
cent tissues, and no association of methylation levels
with therapy response or overall survival. We
observed, however, a higher dispersion of methylation
and expression of miR-7 and MAFG in the T than in
the ATT and in the control samples, suggesting that
different molecular changes in miR-7 and MAFG
could be mediating the carcinogenic process, as has
been observed for other markers.30 We have not specif-
ically observed clear differences either in methylation
or expression of any candidate in NSCLC T versus
ATT samples, which could indicate that the samples
adjacent to the tumor have already acquired molecular
changes probably associated with tumor features as has
been described for other miRNAs.31
Moreover, the methylation analysis of the ATT com-
pared with the five normal saliva samples indicates thatthe methylation of this miRNA is an event that occurs
in the early stages of the disease. This fact suggests
that molecular changes such as miR-7 methylation
within the tumor tissue and surrounding tissue generate
the microenvironment necessary for tumor cells to
grow, and this event could be involved not only in
tumorigenesis but also in other malignancies associated
with smoking.32,33 We could not find a clear correla-
tion in either methylation or miR-7 and MAFG expres-
sions in NSCLC T samples. Although these results are
not as compelling as previously observed with our in
vitro models (ref theranostics), we cannot dismiss the
potential coregulation of epigenetic factors that can
interact with miR-7 andMAFG, like lncRNAs that reg-
ulate miR-7 (CDR1AS), and MAFG expression (MAF-
GAS1) in a more complex dynamic environment like
the human body. A strength of the current study is that
the results are based on an analysis of fresh tissues
from patients with NSCLC, whereas most of the data
in the literature report the expression of miRNAs and
candidate genes from culture cell lines. In accordance
with our “in house” results, we observed a significant
relationship between the expression of MAFG and sur-
vival in our additional large cohort of 1035 patients
analyzed from Moffitt Center and in the public data-
base with 984 from TCGA with a clear trend toward
higher overall survival when MAFG expression is low.
This suggests an oncogenic role of MAFG in lung can-
cer, supporting its potential as a prognostic biomarker.
The mechanistic approach we used in this study was
aimed at directly linking the development of in vitro
CDDP resistance with the overexpression of MAFG
through the decrease of ROS production in our model of
cancer cell lines. It has previously been shown that the
resistance to CDDP in the A2780 cell line is an event
caused by overactivation of the redox-detoxifying path-
way.34 In line with these, the results obtained with the
ROS production assay in our experimental models indi-
cate that CDDP-resistant subtypes have a lesser increase
in ROS after CDDP exposure, probably due to its ability
to detoxify the oxidative stress produced by the drug, as
a consequence of an overexpression of MAFG. We also
found a significant overexpression of reported
redoxdetoxifying-related genes35 in the resistant cell
lines harboring an increased expression of MAFG, rein-
forcing the idea that MAFG mediates the resistance to
CDDP through the modulation of ROS. Indeed, our
results also indicate that MAFG could regulate this pro-
cess in response to CDDP by increasing NRF2 stabiliza-
tion in the nucleus. Therefore, targeting MAFG may
lower NRF2 activity and potentially restore the sensitiv-
ity to the drug.
We then sought to explore new methodologies to
detect and inhibit the action of MAFG in order to
Fig 5. Analysis of MAFG localization pattern in paraffin samples of patients with known levels of MAFG by aptahisto-
chemistry. Samples were incubated with digoxigenin-labeled aptamers apMAFG3F, apMAFG6F, and apMAFG11F as
primary recognition molecules, and afterward with anti-digoxigenin antibodies. Staining was performed using DAB
staining solution. (A) Representative aptahistochemistry pictures showing the areas of analysis in NSCLC tumor sam-
ples; (B) T test comparison between low and high MAFG mRNA levels (2¡DCt) and the % mean ratio of positive cells
analyzed in the areas defined on (A). Positive cells were counted using the Cell Counter on ImageJ software. NSCLC:
non-small cell lung cancer. MAFG, musculoaponeurotic fibrosarcoma oncogene family, protein G.
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Fig 6. Effect of aptamers apMAFG3F, apMAFG6F, and apMAFG11F on cell viability, response to CDDP. (A)
Viability curves combining the selected dose of aptamers (25 nM) and increasing doses of CDDP in H23S/R
cells. #P < 0.05 (Student’s t test). The treatment with aptamer significantly increased the sensitivity to CDDP
(* P < 0.05 and ***< 0.001); (B) Viability curves combining apMAFG6F at 25 nM with increasing doses of
CDDP in H1299 lung cancer cells. (C) Viability curves of H23 cell line transfected with pCMV6 (S- and
R-), with the overexpression vectors (S-MAFG) and the combination of MAFG overexpressing plasmids
together with apMAFG6F at 25 nM. For (A), (B), and (C), each experimental group was exposed for 72 h to 6
different CDDP concentrations after aptamer transfection; data were normalized to each untreated control, set to
100% and represent the mean § SD of at least three independent experiments performed in quadruplicate at
each drug concentration for each cell line analyzed. The CDDP-RI (Resistant Index to CDDP) was calculated as
“IC50 from the Resistant/ IC50 from the Sensitive" and “IC50 from the transfected with aptamers or MAFG/
IC50 from the Sensitive” § SD. (D) Validation of MAFG overexpression and aptamer transfection in the H23S
cells after 72 h of transfection. Top, Relative expression levels of MAFG measured by quantitative RT-PCR, in
the cell line H23, represented in 2¡DDCt scale; In each experimental group, the sensitive cell line transfected
with pCMV6 plasmid was used as a calibrator. Each bar represents the combined relative expression of two inde-
pendent experiments measured in triplicate. Bottom, quantification of apMAFG6F in the cell line H23. Quantifi-
cation was performed according to the absolute quantification method by using a standard curve of known
concentration of aptamers. The amount of protein per sample was used as a control. Data represent the mean of
at least three independent experiments measured by triplicate § SD. CDDP, cisplatin; RT-PCR, real-time poly-
merase chain reaction.
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Fig 7. Effect of aptamer apMAFG6F on response to CDDP and ROS production. (A) Viability and ROS production
assay in H23R cells after apMAFG6F transfection. Each experimental group was exposed for 72 h to 6 different
CDDP concentrations, and data were normalized to each untreated control, set to 100%. The data represent the mean
§ SD of at least four independent experiments performed in duplicate at each drug concentration for each cell line
analyzed. * P < 0.05 was considered as significant change in CDDP resistance and ROS production; (B) Expression
analysis of downstream genes regulated by MAFG involved in ROS detoxification in H23R and H23R transfected
with apMAFG6F. Left, representative images ofMAFG, HMOX1, and GAPDH RT-PCR. Each assay was performed
at least three times to confirm the results. Right, relative intensity quantification of the amplified band for each gene
measured by ImageJ Software. Bars represent the mean of three independent experiments using the intensity of
GAPDH as endogenous control and the resistant subtype of each cell line as calibrator § SD. CDDP, cisplatin; ROS,
reactive oxygen species; MAFG, musculoaponeurotic fibrosarcoma oncogene family, protein G.
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a novel field of research, which has led to important
achievements in therapeutics and diagnosis.14,36 There-
fore, in this study, we aimed to select and characterize
aptamers that are highly specific against MAFG and
that could show potential therapeutic and/or diagnostic
properties in cancer, as has been shown for other
aptamers.15,37 The SELEX technology allowed us to
select and identify three aptamers with high affinity to
MAFG after 6 rounds of selection. Although the three
selected aptamers (apMAFG3F, apMAFG6F, and
apMAFG11F) showed high affinity to the protein with
Kd values in the nanomolar range, apMAFG3F and
apMAFG6F showed the lower Kd and the highest sig-
nal in resistant cells in aptacytochemistry. The fact that
apMAFG6F staining remains preferentially at the
nuclei could indicate that it is, in essence, more specific
for nuclear MAFG. In addition, we observed a greaterpresence of the three aptamers in H23R cells, suggest-
ing greater expression of the protein MAFG in resistant
cells; indeed, this result is in accordance with the high
mRNA levels of MAFG observed in the resistant can-
cer cells.13 We were also able to detect MAFG in
human formalin-fixed paraffin-embedded tumor sam-
ples with known levels of MAFG mRNA. Specifically,
we found the strongest difference between low and
high expression levels of MAFG when using
apMAFG6F staining in the group of samples analyzed.
These results, although preliminary because of the lim-
ited number of samples tested, are promising, indicat-
ing that these aptamers, particularly apMAFG6F, could
be used as potential diagnostic tools to identify patients
with higher expression of MAFG. It is a robust starting
point for future studies involving larger cohorts of
patients to analyze the correlation between aptamer
intensity and patients’ clinical outcome.
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apMAFG6F, and apMAFG11F and CDDP treatment in
resistant lung cancer cells showed that only apMAFG6F
can change the response to CDDP, partially restoring the
sensitivity to the drug, without causing cell mortality in nor-
mal cells. In fact, even when MAFG was overexpressed,
inducing an increase of platinum resistance in H23 sensitive
cells, apMAFG6F was able to revert the resistance to plati-
num. This resensitization was promoted by an increase in
ROS production, probably mediated by a decrease in the
expression of antioxidant genes such as HMOX1, as previ-
ously shown.38-40 We also observed a decrease in MAFG
expression levels when transfecting apMAFGF6, which
suggests an auto-regulation of MAFG transcription and is
consistent with the fact that MAFG shows ARE motifs on
its regulatory region.10,41 Therefore, our results present a
newmechanism for restoring CDDP sensitivity in lung can-
cer through the use of aptamer apMAFG6F.
Taken together, our experimental results strongly sup-
port the role of MAFG in the development of CDDP resis-
tance through ROS detoxification. To the best of our
knowledge, this is the first report describing the possible
role ofMAFG expression as a biomarker of poor prognosis
in NSCLC and its potential as a therapeutic and diagnostic
target in cancer and other pathologies through the use of
aptamers. D35X X
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